Free Newsletter
Gates gives $168M for research into malaria vax
The Bill and Melinda Gates Foundation is putting up $168 million to fund research into a new generation of malaria vaccines. The initiative is one of a broad range of new efforts around the globe aimed at eradicating malaria by 2015.
At a recent summit at the UN, donors committed $3 billion to the war against malaria. The World Bank and the Global Fund to Fight Aids, Tuberculosis and Malaria is putting up the lion's share of that money, with the British government and the Gates Foundation providing the rest. The donors believe that their efforts can save more than 4 million lives over the next seven years.
"We need innovation, new drugs, and the most dramatic thing we need is vaccine," says Gates.
The Gates foundation has donated nearly $1.5 billion to malaria research over the past 8 years. The organization came under scrutiny back in February when WHO malaria chief, Dr. Arata Kochi accused the Foundation of creating funding practices among their network of top malaria scientists that caused scientists' research to be linked to those of others in the group, making it difficult for scientists to objectively evaluate each other's work. The Foundation denied that claim.
- check out the Gates Foundation release
- read the article from the BBC
Related Articles:
Genzyme joins malaria drug research consortium
Sanaria takes new approach for malaria vaccine
Gates backs vaccine tech for developing countries
Gates Foundation fuels malaria programs
Gates Foundation readies $258M for new malaria programs
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession




